BioStock: Annexin's phase II study fully recruited with positive signals

Annexin Pharmaceuticals has announced that the final patient has been treated in the phase II study with ANXV for the eye disease retinal vein occlusion. A total of 15 patients have been treated, and the results so far show a favorable safety profile and promising efficacy signals. The company is expected to present top-line data during the summer of 2024.

Read the article about Annexin Pharmaceuticals here:

https://www.biostock.se/en/2024/04/annexins-phase-ii-study-fully-recruited-with-positive-signals/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/